- さらに表示:
Wikipedia ですべてを見てくださいOsimertinib - Wikipedia
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin … 詳細
Osimertinib is used to treat locally advanced or metastatic non-small-cell lung cancer (NSCLC), if the cancer cells are positive for the T790M mutation in the gene coding for EGFR or for activating EGFR mutations. The T790M … 詳細
Economics
At launch, in the United States AstraZeneca priced the drug at $12,750 per month. 詳細Very common (greater than 10% of clinical trial subjects) adverse effects include diarrhea, stomatitis, rashes, dry or itchy skin, 詳細
Osimertinib preferentially binds irreversibly to mutated epidermal growth factor receptor proteins, particularly those with more common mutations … 詳細
The drug discovery program that led to osimertinib started in 2009 and yielded the drug by 2012; the process was structure-driven and aimed to find … 詳細
CC-BY-SA ライセンスに準拠した Wikipedia テキスト Osimertinib or Platinum–Pemetrexed in EGFR T790M ...
ウェブ2017年2月16日 · Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with...
- 作成者: Tony S. Mok, Yi Long Wu, Myung Ju Ahn, Marina C. Garassino, Hye Ryoun Kim, Suresh S. Ramalingam, Fra...
- Publish Year: 2017
- 他の人はこちらも質問
Osimertinib Resistance: Molecular Mechanisms and ...
ウェブ2023年1月30日 · Timeline of development and approvals of osimertinib. Abbreviations: EGFR: epidermal growth factor receptor, TKI: tyrosine kinase inhibitor, FDA: Food and …
A consensus on the role of osimertinib in non-small cell lung ...
ウェブ2018年5月28日 · Osimertinib (AZD9291 or Tagrisso) is a structurally mono-anilino-pyrimidine compound, orally available, third-generation EGFR-TKI that irreversibly …
Identification of Novel Pathways of Osimertinib …
ウェブ2018年4月30日 · Wild-type and h2D6 animals were administered osimertinib (25 mg/kg p.o.) and blood samples collected at the indicated timepoints for measurement of (C) osimertinib and (D) OH-2-osimertinib. Data shown are mean ± SD with n = 4 in each group.
Osimertinib successfully combats EGFR-negative ...
ウェブ2020年5月12日 · In GBM patient-derived xenografts mice, oral administration of osimertinib (40 mg· kg −1 ·d −1, for 18 days) significantly suppressed the tumor …
Osimertinib with Chemotherapy in EGFR -Mutated NSCLC
ウェブ2024年1月31日 · Abstract. To the Editor: In the report by Planchard et al. (Nov. 23 issue) 1 on the FLAURA2 trial of osimertinib with or without chemotherapy in EGFR …
Osimertinib as first-line treatment for advanced epidermal ...
ウェブ2021年12月1日 · Osimertinib is used in the second-line treatment because of the resistance imparted by T790M, and therefore, the optimal first-line treatment for …
Distinct Progression and Efficacy of First-Line Osimertinib ...
ウェブ2024年1月17日 · PFS and OS were estimated using the Kaplan–Meier method, and comparisons were performed with the log-rank test. PFS was defined as the duration …
ウェブosimertinib administration at any dose, the progression-free survival (PFS) for patients receiving 40 mg of osimertinib every other day, and relative dose intensity (RDI) of …
Osimertinib routes of administration に関連する検索
- 一部の検索結果が削除されました
コンテンツに移動
